Physician profile

Anuj Suri

Gynecologic Oncology · Houston, TX

NPI 1326366691

$72,479.12

in general payments reported to CMS, 2019-2025

45 companies · $17K in 2025

The $17K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$12,244.00
Consulting Fee$9,120.00
Honoraria$8,860.00
Food and Beverage$3,751.09
Travel and Lodging$2,615.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pacira Pharmaceuticals Incorporated $48,130.06 2019-2025 Exparel, Iovera, Zilretta
Intuitive Surgical, INC. $13,217.42 2023-2025 Da Vinci Surgical System
Baxter Healthcare $4,808.59 2020-2025 Floseal, Perclot, Tisseel
Ethicon INC. $2,020.00 2022
Merck Sharp & Dohme LLC $423.49 2021-2025 Keytruda, Lynparza, Keytruda Qlex
Glaxosmithkline, LLC. $386.04 2020-2025 Zejula, Jemperli
Myriad Genetic Laboratories, INC. $375.27 2021-2024 Myrisk, Precisetumor
Bayer Healthcare Pharmaceuticals INC. $367.84 2019-2023
Eisai INC. $277.47 2019-2025
Astellas Pharma US INC $250.74 2022-2024 Veozah, Cresemba
Davol INC. $212.88 2022-2025 Arista Ah Flexitip, Arista
Dilon Technologies, INC. $195.82 2025 Hemoblast Bellows
Myovant Sciences INC. $176.71 2021-2022
Abbvie INC. $167.49 2019-2025 Orilissa, Lo Loestrin Fe
Duchesnay USA Incorporated $121.36 2019
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $115.28 2019-2024
Daiichi Sankyo INC. $101.97 2021-2023 Injectafer
Therapeuticsmd, INC. $101.59 2019-2022
Tesaro, INC. $89.85 2019
Mayne Pharma Commercial LLC $80.57 2022-2023
Scynexis, INC. $77.27 2022
Sumitomo Pharma America, INC. $76.69 2023-2025 Myfembree
Aspira Women'S Health INC $68.27 2019-2024 Ova1
Ethicon US, LLC $64.17 2020-2022
Genmab U.S., INC. $60.45 2024-2025 Tivdak
Clovis Oncology, INC. $52.45 2019
Organon LLC $50.54 2022-2023 Nexplanon
Smith+Nephew, INC. $49.12 2023 Stravix Pl
Caris Mpi, INC. $41.88 2025 Mi Cancer Seek
Baudax Bio INC. $39.30 2021
Integra Lifesciences Corporation $37.34 2023 Duraseal Exact Spinal Sealant System, Codman Hakim, Cusa Clarity
Medtronic, INC. $26.86 2022
Medical Device Business Services, INC. $24.39 2025 Enseal
Alexion Pharmaceuticals, INC. $22.99 2022
Biom'Up Sa $19.47 2019
Sanara Medtech INC. $17.16 2021
Amag Pharmaceuticals, INC. $15.50 2019
Hologic Sales and Service, LLC $15.40 2023 Affirm Prone Biopsy System
Millicent US INC $15.28 2024 Femring, Intrarosa
Evofem Biosciences, INC. $15.24 2022
Coopersurgical, INC. $14.90 2022
Meditrina $14.58 2024
Kci USA, INC. $14.29 2020
Novo Nordisk INC $13.02 2019
Lupin INC. $12.12 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anuj Suri

$72,479.12

in general payments reported 2019-2025

Years
2019-2025
Top company
Pacira Pharmaceuticals Incorporated
Context
The $17K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).

https://glasscript.com/doctor/332973/anuj-suri

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.